Cargando…
Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
ErbB2, a member of the ErbB family of receptor tyrosine kinases, is an essential player in the cell’s growth and proliferation signaling pathways. Amplification or overexpression of ErbB2 is observed in ∼30% of breast cancer patients, and often drives cellular transformation and cancer development....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833446/ https://www.ncbi.nlm.nih.gov/pubmed/29352243 http://dx.doi.org/10.1038/s41419-017-0067-7 |